according to the xinhua news agency, 2Month14On the afternoon of the 15th, Xi Jinping, General Secretary of the CPC Central Committee, President of the State, Chairman of the Central Military Commission, and Director of the Central Committee for Comprehensively Deepening Reform, presided over the twelfth meeting of the Central Committee for Comprehensively Deepening Reform and delivered an important speech.

The twelfth meeting of the Central Committee for Comprehensively Deepening Reform clarified that it is necessary to incorporate biosafety into the national security system from the perspective of protecting people's health, ensuring national security, and maintaining the country's long-term stability, and systematically plan the construction of the national biosafety risk prevention and control and governance system, and comprehensively improve National biosafety governance capabilities. To promote the introduction of biosafety law as soon as possible, accelerate the construction of national biosafety laws and regulations system, system guarantee system.

1,1Month28day,2019YearPfizer(Pfizer) Earnings Disclosure, Vaccine Division Revenue65.04Billion US dollars, year-on-year growth3%,13Valid pneumonia conjugate vaccine (Prevnar 13/Prevenar 13.) sales reach58.47Billion US dollars, year-on-year growth1%,ACWYMeningitis Vaccine (Nimenrix) sales reach2.3Billion US dollars, year-on-year growth65%Vaccine against tick-borne encephalitis (FSME/IMMUN-TicoVac) sales reach2.2Billion US dollars, year-on-year growth20%,BMeningitis Vaccine (Trumenba) sales reach1.35Billion US dollars, year-on-year growth16%The main source of revenue for the vaccine sector is13Price pneumonia combined vaccine, future performance growth space is limited.

2,2Month5day,2019YearGSK(GSK) earnings disclosure, vaccine segment revenue72billion pounds (equivalent94billion dollars), year-on-year growth19%The revenue growth was mainly due to the market contribution of herpes zoster vaccine and meningitis vaccine, of which herpes zoster vaccine (Shingrix) sales reach18.1Billion pounds, year-on-year growth131%, will be2020into the Chinese and Japanese markets in batches, meningitis vaccines,BMeningitis Vaccine (Bexvero) sales reach6.79Billion pounds, year-on-year growth16%,ACWYMeningitis Vaccine (Menveo) sales reach2.67Billion pounds, year-on-year growth15%; monovalent rotavirus vaccine (Rotarix) Sales5.58Billion pounds, year-on-year growth7%;2Valid cervical cancer vaccine (Cervarix) Sales0.5billion pounds,Year-on-year decline64%。

 3、2Month5day,2019YearMSD(Merck) Earnings Disclosure, Vaccine Division Revenue84Billion US dollars, year-on-year growth15%The revenue growth was mainly due to the market contribution of cervical cancer vaccine and four pox vaccine, of which cervical cancer vaccine (4PriceGarage baseand9PriceGardasil 9) sales reach37.37Billion US dollars, year-on-year growth19%, four pox vaccine (PROQUAD, M-M-R II and VARIVAX) Sales22.75Billion US dollars, year-on-year growth27%,23Valency pneumococcal polysaccharide vaccine (PNEUMOVAX 23）9.26Billion US dollars, year-on-year growth2%,5Valuable oral rotavirus vaccine (ROTATEQ) Sales7.91Billion US dollars, year-on-year growth9%;2019Mercadon's sales in China grew rapidly in58%Cervical cancer vaccine is a very important growth point.

4、2Month6day,2019YearSANOFI(Sanofi) earnings disclosure, vaccine segment revenue57.31billion euros (equivalent62.06billion dollars), year-on-year growth9.3%, revenue growth came mainly from polyvaccine and influenza vaccines, with polyvaccine and rabies vaccine (Hexaxim,Pentacel, Pentaxin, Imovax) Total Sales19.46Billion euros, year-on-year growth9.8%, influenza vaccine (Vaxigrip,Fluzone HD,Fluzone, Flustok) Sales18.91Billion euros, year-on-year growth7.3%。

5、2Month18On the same day, Changchun Baike (a subsidiary of Changchun High-tech) registered a live attenuated herpes zoster vaccine.IIIPhase I clinical trial to evaluate live attenuated herpes zoster vaccine30days after the protective efficacy of prevention of herpes zoster, the target enrollment reached2.5Ten thousand people.